CG
ALNY icon

Clinton Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Clinton Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,637
Closed -$378K – 311
2014
Q1 		$378K Buy
5,637
+200
+4% +$15.5K 0.14% 224
2013
Q4 		$350K Buy
+5,437
New +$324K 0.12% 208

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Clinton Group's ALNY Position: Q2 2014 in Review

Clinton Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2014, closing a stake of 5,637 shares — an estimated $378K sold.

Clinton Group first reported a position in ALNY in Q4 2013 and held it in 2 quarters. The position peaked at $378K in Q1 2014. 194 funds tracked by Wall St. Rank hold ALNY as of Q2 2014.

  • Clinton Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Clinton Group sold 5,637 Alnylam Pharmaceuticals shares in Q2 2014, an estimated $378K.
  • Clinton Group first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 2 quarters.
  • Clinton Group's Alnylam Pharmaceuticals position peaked at $378K in Q1 2014.
  • 194 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2014.

Based on Clinton Group's 13F filing for Q2 2014, filed 14 Aug 2014.